009: CMC Considerations For In-Human Studies with Drs. Edith Perez a Nathan Ihle
Bolt Biotherapeutics CMO Dr. Edith Perez and VP of CMC a Quality Dr. Nathan Ihle bring a unique combination of patient and production process expertise to the table for an enlightening conversation on preparing chemistry, manufacturing, and controls for an IND and ensuing first in-human studies.
